Perrigo Company plc (PRGO)
| Previous close | 29.94 |
| Open | 29.92 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 900 |
| Day's range | 29.82 - 30.59 |
| 52-week range | 25.77 - 40.28 |
| Volume | |
| Avg. volume | 2,000,724 |
| Market cap | 4.133B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.10 (3.66%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- Insider Monkey
Here’s Why Perrigo Company PLC (PRGO) Stock Slumped in Q1
Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The portfolio had a 5.7% gain in the first quarter compared to an 8.2% return in the Russell Midcap Value Index. The Strategy underperformed in Financials and Industrials due […]
- Fortune
The WNBA has partnered with Glossier and Skims—now it’s added Opill, the new over-the-counter birth control
Pharma company Perrigo plans to spread the word about Opill at the WNBA draft.
- Reuters
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors
CVS Caremark, the pharmacy benefit management subsidiary of CVS Health Corp, will add Perrigo's birth control pill to its preventive services oral contraceptives list and make it available at no cost for many plan sponsors, according to a pharmacy update on March 28. The U.S. FDA in July approved over-the-counter use of Perrigo's drug Opill, making it the first oral contraceptive in the country which can be purchased without prescription.
